Carl P. Blobel
Has grant
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
Recent Grants
Grant: Close
iRhom2, a New Target for Treatment of TNF-Alpha-Dependent Pathologies
Open Date: 2013-06-21
Close Date: 2014-12-20
Grant: Close
Matrix Metalloproteinases Gordon Conference
Open Date: 2005-06-01
Close Date: 2010-05-31
Grant: Close
Role of ADAMs 9 and 15 in Proliferative Retinopathy
Open Date: 2004-09-06
Close Date: 2010-08-31
Grant: Close
iRhoms 1 and 2: Key regulators of ADAM17-dependent EGFR signaling
Open Date: 2002-02-01
Close Date: 2020-03-31
Grant: Close
METALLOPROTEASE DISINTEGRIN MDC9
Open Date: 1999-02-01
Close Date: 2004-01-31
Articles (4)
Tylosis with oesophageal cancer (TOC) is a rare familial disorder caused by cytoplasmic mutations in inactive rhomboid 2 (iRhom2 or iR2, encoded by Rhbdf2). iR2 and the related iRhom1 (or iR1, encoded by Rhbdf1) are key regulators of the membrane-anchored metalloprotease ADAM17, which is required for activating EGFR ligands and for releasing pro-inflammatory cytokines such as TNFα (or TNF). A cytoplasmic deletion in iR2, including the TOC site, leads to curly coat or bare skin (cub) in mice, whereas a knock-in TOC mutation (toc) causes less severe alopecia and wavy fur. The abnormal skin and hair phenotypes of iR2cub/cub and iR2toc/toc mice depend on amphiregulin (Areg) and Adam17, as loss of one allele of either gene rescues the fur phenotypes. Remarkably, we found that iR1−/− iR2cub/cub mice survived, despite a lack of mature ADAM17, whereas iR2cub/cub Adam17−/− mice died perinatally, suggesting that the iR2cub gain-of-function mutation requires the presence of ADAM17, but not its catalytic activity. The iR2toc mutation did not substantially reduce the levels of mature ADAM17, but instead affected its function in a substrate-selective manner. Our findings provide new insights into the role of the cytoplasmic domain of iR2 in vivo, with implications for the treatment of TOC patients.
Year:
2023
Year:
2022
Year:
2021
Year:
2020
Collaborators (1)
Stefan Lichtenthaler
Technical University of Munich
Make your next move.
Prepare your application
Review drafts before you send them.